Clinical distribution and drug resistance analysis of 154 strains of Citrobacter
Objective To investigate the clinical distribution and drug resistance of Citrobacter in nosocomial infection.Methods VITEK 2 automatic microbiological analyzer and GNI and GNS-13 were used to identify Citrobacter isolated from January 2013 to December 2022 and to conduct drug susceptibility tests.The results were analyzed using WHONET5.6 software.Results A total of 154 strains of Citrobacter were isolated,mainly from urine samples(53.25%),followed by pus/incision(16.88%).Among them,Citrobacter freundii was the most,accounting for 49.35%,followed by Citrobacter kirschi,accounting for 33.12%.The resistance rate of Citrobacter to cefazolin ranged from 97.8%to 100%,and the resistance rate to carbapenems was 0.0%.The resistance rate to third-generation or fourth-generation cephalosporins,cefotetan,aztreonam,gentamicin,tobramycin and quinolones were all less than 15.8%,and the resistance rate to piperacillin/tazobactam and nitrofurantoin were less than 1.7%.The resistance rate to co-trimoxazole was between 11.8%and 40.8%.Conclusion The drug resistance mechanism of Citrobacter is complex,and clinical practice should be guided by drug susceptibility results.Piperacillin/tazobactam and nitrofurantoin could be used as the first-choice drugs.
NETL
NSTL
万方数据
